Actively Recruiting
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Led by Alberta Health services · Updated on 2023-01-05
500
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]
CONDITIONS
Official Title
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female; females of child-bearing potential must have a negative pregnancy test if more than 10 days since last menstrual period
- Age 18 years or older
- Able and willing to follow instructions and comply with the study protocol
- Provide written informed consent before participating
- Clinically suspected or biopsy-proven neuroendocrine tumor
You will not qualify if you...
- Pregnant or nursing females
- Age under 18 years
- Surgery in the area of interest within the past 2 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Foothills Medical Center 1403 29 St NW
Calgary, Alberta, Canada, T2N 2T9
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here